Burtseva E I, Vlasova L N, Shevchenko E S, Sabanin Iu V, Rikhter V V, Artiukov R M, Rybin V V, Tarasevich N N, Slepushkin A N
Ivanovsky Research Institute of Virology, Military Medical Command, Ministry of Internal Affairs, Moscow, Russia.
Zh Mikrobiol Epidemiol Immunobiol. 2004 Jan-Feb(1):49-55.
The immunization properties of the influenza vaccine Vaxigrip, used in combination with vaccines against pneunococcal infection and hepatitis A (respectively, Pneumo 23 and Avaxim), were evaluated. In Central Russia in one of the units of the internal forces of the RF Ministry of Internal Affairs 3 groups totaling 755 servicemen were formed, depending on the complex of the introduced vaccines. Active medical observation and the registration of the complaints of the vaccinees at the postvaccinal period did not reveal unusual reactions and complications in none of the groups under observation. In the evaluation of the level of specific antibodies to the circulating influenza viruses prior to vaccination the low level of collective protection to influenza B virus was determined: protective antibody levels were registered only in 14-18% of the servicemen, while the corresponding data with respect of influenza viruses A(H1N1) and A(H3N2) were 45-50% and 56-63% respectively. At the same time, in seronegative persons the vaccine Vaxigrip exhibited high immunogenic activity with respect of all 3 influenza strains; seroconversion to them was determined in 84-92% of the vaccines, and the level of protective antibody titers before the beginning of the epidemic season was 86-99% in the whole of the group. The characteristics of the prophylactic effectiveness of the vaccine Vaxigrip in relation to the influenza virus infection level 1 were 4.7 (index) and 79% (coefficient). In addition, the frequency of influenza cases, clinically pronounced and confirmed by laboratory methods, in patients who had been immunized with 3 vaccines was 6.7%, which was 10.3 times less frequent than number of cases in the groups of comparison (68.2% on the average). The coefficient of epidemiological effectiveness of the prophylaxis of influenza was 90.2%. The complex use of 3 preparations did not affect the immunization properties of the vaccine Vaxigrip.
对与抗肺炎球菌感染疫苗和甲型肝炎疫苗（分别为肺炎23价疫苗和安尔宝）联合使用的流感疫苗“维克菲”的免疫特性进行了评估。在俄罗斯中部俄罗斯内政部内卫部队的一个单位中，根据所接种疫苗的组合，组建了3组共755名军人。在疫苗接种后阶段进行的主动医学观察以及对接种者投诉的记录显示，在所有观察组中均未发现异常反应和并发症。在接种疫苗前对循环流感病毒的特异性抗体水平进行评估时，确定对乙型流感病毒的集体保护水平较低：仅在14 - 18%的军人中检测到保护性抗体水平，而对于甲型（H1N1）和甲型（H3N2）流感病毒，相应的数据分别为45 - 50%和56 - 63%。同时，在血清阴性的人群中，“维克菲”疫苗对所有3种流感毒株均表现出高免疫原性活性；在84 - 92%的接种者中检测到血清转化，并且在整个组中流行季节开始前保护性抗体滴度水平为86 - 99%。“维克菲”疫苗针对1级流感病毒感染水平的预防效果特征为4.7（指数）和79%（系数）。此外，接种3种疫苗的患者中，经实验室方法临床确诊的流感病例发生率为6.7%，这比对照组的病例数（平均68.2%）少10.3倍。流感预防的流行病学效果系数为90.2%。3种制剂的联合使用未影响“维克菲”疫苗的免疫特性。
